Your browser doesn't support javascript.
loading
Abiraterone In Vitro Is Superior to Enzalutamide in Response to Ionizing Radiation.
Wright, Timothy C; Dunne, Victoria L; Alshehri, Ali H D; Redmond, Kelly M; Cole, Aidan J; Prise, Kevin M.
Afiliação
  • Wright TC; Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, United Kingdom.
  • Dunne VL; Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, United Kingdom.
  • Alshehri AHD; Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, United Kingdom.
  • Redmond KM; Department of Radiological Science, College of Applied Medical Sciences, Najran University, Najran, Saudi Arabia.
  • Cole AJ; Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, United Kingdom.
  • Prise KM; Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast, Belfast, United Kingdom.
Front Oncol ; 11: 700543, 2021.
Article em En | MEDLINE | ID: mdl-34367984
ABSTRACT
Abiraterone acetate and Enzalutamide are novel anti-androgens that are key treatments to improve both progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer. In this study, we aimed to determine whether combinations of AR inhibitors with radiation are additive or synergistic, and investigated the underlying mechanisms governing this. This study also aimed to compare and investigate a biological rationale for the selection of Abiraterone versus Enzalutamide in combination with radiotherapy as currently selection is based on consideration of side effect profiles and clinical experience. We report that AR suppression with Enzalutamide produces a synergistic effect only in AR-sensitive prostate models. In contrast, Abiraterone displays synergistic effects in combination with radiation regardless of AR status, alluding to potential alternative mechanisms of action. The underlying mechanisms governing this AR-based synergy are based on the reduction of key AR linked DNA repair pathways such as NHEJ and HR, with changes in HR potentially the result of changes in cell cycle distribution, with these reductions ultimately resulting in increased cell death. These changes were also shown to be conserved in combination with radiation, with AR suppression 24 hours before radiation leading to the most significant differences. Comparison between Abiraterone and Enzalutamide highlighted Abiraterone from a mechanistic standpoint as being superior to Abiraterone for all endpoints measured. Therefore, this provides a potential rationale for the selection of Abiraterone over Enzalutamide.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article